Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Strezova, Ana, Diez-Domingo, Javier, Al Shawafi, Kamal, Tinoco, Juan Carlos, Shi, Meng, Pirrotta, Paola, Mwakingwe-Omari, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588150/
https://www.ncbi.nlm.nih.gov/pubmed/36299530
http://dx.doi.org/10.1093/ofid/ofac485
Descripción
Sumario:Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.

Ejemplares similares